Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
C4 THERAPEUTICS, INC. | Delayed Nasdaq 04:00:00 2023-09-22 pm EDT |
|
5-day change | 1st Jan Change | |
| 2.040 USD | -6.85% | -8.52% | -65.42% | |
| Sep. 18 | ImmunoGen Names Lauren White CFO | MT |
| Sep. 06 | C4 Therapeutics Appoints Kendra Adams as Finance Chief | MT |
Financials (USD)
| Sales 2023 * | 19 M | Sales 2024 * | 22 M | Capitalization | 108 M |
|---|---|---|---|---|---|
| Net income 2023 * | -148 M | Net income 2024 * | -189 M | EV / Sales 2023 * | -9,84x |
| Net cash position 2023 * | 291 M | Net cash position 2024 * | 204 M | EV / Sales 2024 * | -4,42x |
| P/E ratio 2023 * | -0,80x | P/E ratio 2024 * | -0,80x | Employees | - |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 92.20% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.90% | ||
| 1 week | -4.37% | ||
| Current month | -24.48% | ||
| 1 month | -32.82% | ||
| 3 months | -26.01% | ||
| 6 months | -44.97% | ||
| Current year | -62.88% |
1 week
2.05
2.31
1 month
2.053.43
Current year
2.059.41
1 year
2.0510.42
3 years
2.0551.21
5 years
2.0551.21
10 years
2.0551.21
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Hirsch
CEO | Chief Executive Officer | 52 | 2020 |
Kendra Adams
DFI | Director of Finance/CFO | 47 | Sep. 17 |
Stewart Fisher
CTO | Chief Tech/Sci/R&D Officer | 56 | 2018 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bruce Downey
CHM | Chairman | 75 | - |
Glenn Dubin
BRD | Director/Board Member | 66 | 2021 |
Kenneth Anderson
BRD | Director/Board Member | 71 | 2015 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-22 | 2.040 | -6.85% | 313 094 |
| 23-09-21 | 2.190 | -0.90% | 169,342 |
| 23-09-20 | 2.210 | 0.00% | 212,197 |
| 23-09-19 | 2.210 | +2.79% | 342,523 |
| 23-09-18 | 2.150 | -3.59% | 2,342,226 |
Delayed Quote Nasdaq, September 21, 2023 at 04:00 pm EDT
More quotes
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. It leverages its technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to design and optimize small-molecule medicines that harness the body's natural protein recycling system to rapidly degrade disease-causing proteins. Its TORPEDO platform enables the discovery of targeted investigational small molecule medicines called protein degraders. Its advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma (MM), and non-Hodgkin lymphomas (NHLs). Its other product candidate, CFT8634, is an orally bioavailable BiDAC degrader of a protein target called BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.
Calendar
2023-11-15
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2.190USD
Average target price
19.00USD
Spread / Average Target
+767.58%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -62.88% | 108 M $ | |
| +58.41% | 107 M $ | |
| -46.17% | 106 M $ | |
| -78.14% | 106 M $ | |
| +5.45% | 106 M $ | |
| -20.00% | 106 M $ | |
| -12.47% | 110 M $ | |
| -17.26% | 105 M $ | |
| -1.74% | 104 M $ | |
| -75.22% | 104 M $ |
